Champions Oncology, Inc. (CSBR) EPS Estimated At $0.04

November 11, 2018 - By Ann Prendergast

Champions Oncology, Inc. (NASDAQ:CSBR) Logo

Analysts expect Champions Oncology, Inc. (NASDAQ:CSBR) to report $0.04 EPS on December, 6.They anticipate $0.05 EPS change or 500.00 % from last quarter’s $-0.01 EPS. CSBR’s profit would be $446,577 giving it 86.25 P/E if the $0.04 EPS is correct. After having $0.04 EPS previously, Champions Oncology, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.29% or $0.18 during the last trading session, reaching $13.8. About 87,348 shares traded. Champions Oncology, Inc. (NASDAQ:CSBR) has risen 168.61% since November 11, 2017 and is uptrending. It has outperformed by 152.99% the S&P500.

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. The company has market cap of $154.07 million. The Company’s Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It currently has negative earnings. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services.

More recent Champions Oncology, Inc. (NASDAQ:CSBR) news were published by: Seekingalpha.com which released: “UAA, WFT, AKAM and SN among midday movers (10/30/2018)” on October 30, 2018. Also Benzinga.com published the news titled: “55 Stocks Moving In Tuesday’s Mid-Day Session” on October 30, 2018. Seekingalpha.com‘s news article titled: “Amedisys among healthcare gainers; Community Health Systems leads losers” with publication date: October 30, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: